PCOS as a Cardiometabolic Condition: What the 2023 International Guideline Recommends Testing

The 2023 International Evidence-based PCOS Guideline recognizes polycystic ovary syndrome as a cardiometabolic condition carrying elevated diabetes and cardiovascular risk, yet it advises against routine fasting-insulin and insulin-resistance indices in care. It instead recommends the oral glucose tolerance test, HbA1c, and a lipid profile at diagnosis. That gap between a real mechanism and a recommended test is the whole story worth understanding.

A plausible mechanism is not automatically a screening test

Insulin resistance sits near the center of how PCOS is explained. It links the ovarian, metabolic, and reproductive features into one coherent picture, and it is genuinely present in a large share of people with the syndrome. So the intuitive move is to measure it directly: draw a fasting insulin level, or calculate an index like HOMA-IR, and use the number to gauge risk.

The 2023 guideline, published across journals including the Journal of Clinical Endocrinology and Metabolism, declines to make that move. Its practice point is blunt: insulin resistance is a pathophysiological factor in PCOS, but clinically available insulin assays are of limited clinical relevance and should not be used in routine care. A mechanism can be real and central and still fail to yield a useful test. Those are separate questions, and the guideline keeps them separate.

The reason is measurement. Insulin assays are not standardized across laboratories the way glucose or cholesterol assays are, so the same blood sample can produce different numbers depending on where it is run. Fasting insulin also varies substantially within the same person from day to day. Indices built on those inputs inherit the noise. A test that is imprecise, poorly standardized, and lacking validated action thresholds does not sharpen a decision. It adds a number that looks quantitative without reliably changing what anyone should do next. This is a recurring pattern in evidence appraisal: the biological story and the analytic performance of the assay are judged on different evidence, and a test earns its place only by clearing the second bar.

What the guideline does recommend, and why

Having set insulin measurement aside, the guideline does not soften its view of the underlying risk. It replaces the appealing-but-unreliable test with ones that perform.

For glucose status, the strong recommendation is the 75-gram oral glucose tolerance test (OGTT) as the most accurate assessment, applied regardless of body mass index. That last clause matters. It refuses the common shortcut of screening only people in a higher weight category, because dysglycemia in PCOS is not confined to them. Fasting plasma glucose or HbA1c can be considered as alternatives, but the guideline explicitly notes their reduced accuracy relative to the OGTT in this population. That is an honest ranking rather than a menu of equals.

For cardiovascular risk, the guideline requires a fasting lipid profile at diagnosis, covering total cholesterol, LDL, HDL, and triglycerides, along with regular blood pressure measurement. These are not exotic tests. They are the same well-standardized measures used across general cardiovascular prevention, chosen precisely because their performance and interpretation are established.

The pattern is consistent. Where an assay is reliable and tied to a decision, the guideline recommends it. Where the biology is compelling but the assay is not, it holds back. The direction of risk never disappears from view; only the unreliable instrument does.

The evidence behind calling PCOS cardiometabolic

The claim that PCOS carries elevated cardiovascular risk rests on aggregated data, and the guideline commissioned it directly. A 2024 systematic review and meta-analysis in the Journal of the American Heart Association pooled studies on clinical cardiovascular events specifically to inform the guideline update. Its pooled odds ratios showed significant associations between PCOS and composite cardiovascular disease, composite ischemic heart disease, myocardial infarction, and stroke.

Two caveats belong in the same breath as those findings. First, the analysis did not find a significant association with cardiovascular death, so the signal is clearer for events than for mortality. Second, these are observational, pooled estimates. They establish elevated risk at the population level and justify universal risk assessment; they do not license precise individual prediction, and the studied populations vary in how PCOS was defined and how confounders such as weight were handled. Naming those limits is not a hedge. It is what separates a defensible screening recommendation from an overclaim.

This is also where the logic closes its loop. The evidence supports assessing cardiovascular risk in everyone with PCOS, which the guideline endorses. It does not support routine insulin measurement as the vehicle for that assessment. Elevated risk at the population level and a reliable test for the individual are, once again, two different things, and the guideline answers each on its own evidence.

Why this distinction is worth keeping

The temptation to measure insulin directly is understandable, and the appeal of a single number that captures a mechanism is strong. But a screening recommendation is a claim about what a test reliably tells you and what you can act on, not a claim about what the biology suggests should exist. The 2023 guideline models that discipline in one condition: it takes the cardiometabolic risk seriously, recommends standardized glucose and lipid testing, and declines the plausible-sounding insulin assay because the measurement cannot carry the decision.

This article is educational and not a substitute for individual medical advice; testing decisions belong with your own clinician. What generalizes is the appraisal habit: ask not only whether a mechanism is real, but whether the test for it is accurate, standardized, and tied to an action.